 |
| 25-Feb-13 | Upgrade |
UBS |
Neutral → Buy |
$115 → $130 |
|
| 12-Feb-13 | Reiterated |
Deutsche Bank |
Hold |
$110 → $115 |
|
| 04-Feb-13 | Upgrade |
Canaccord Genuity |
Hold → Buy |
$128 |
|
| 04-Feb-13 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$109 → $111 |
|
| 28-Jan-13 | Initiated |
RBC Capital Mkts |
Sector Perform |
$109 |
|
| 08-Nov-12 | Downgrade |
Caris & Company |
Buy → Above Average |
$136 → $129 |
|
| 05-Nov-12 | Upgrade |
Barrington Research |
Mkt Perform → Outperform |
$142 |
|
| 14-Sep-12 | Upgrade |
Caris & Company |
Above Average → Buy |
$131 → $136 |
|
| 12-Jul-12 | Downgrade |
Canaccord Genuity |
Buy → Hold |
$125 → $125 |
|
| 15-May-12 | Initiated |
Stifel Nicolaus |
Buy |
$125 |
|
| 19-Apr-12 | Downgrade |
Caris & Company |
Buy → Above Average |
|
|
| 17-Apr-12 | Initiated |
Auriga |
Buy |
$125 |
|
| 05-Mar-12 | Upgrade |
Canaccord Genuity |
Hold → Buy |
$125 |
|
| 05-Mar-12 | Reiterated |
UBS |
Buy |
$115 → $120 |
|
| 28-Oct-11 | Upgrade |
Caris & Company |
Above Average → Buy |
$120 → $125 |
|
| 03-Oct-11 | Initiated |
Deutsche Bank |
Hold |
$100 |
|
| 28-Sep-11 | Reiterated |
UBS |
Buy |
$100 → $115 |
|
| 28-Sep-11 | Reiterated |
Collins Stewart |
Buy |
$100 → $117 |
|
| 28-Sep-11 | Reiterated |
Caris & Company |
Above Average |
$106 → $120 |
|
| 22-Jul-11 | Reiterated |
Caris & Company |
Above Average |
$104 → $109 |
|
|
 |
| 18-Jun-13 11:10AM | Perrigo in Expansion Mode Zacks |
| 17-Jun-13 11:15AM | Perrigo acquires eye-care portfolio from Fera AP |
| 08:36AM | InPlay: Perrigo acquires ophthalmic product portfolio from Fera Pharmaceuticals for an upfront payment of $93 mln; expected to be more than $0.12 accretive to adjusted EPS for fiscal 2014 Briefing.com |
| 08:35AM | Perrigo acquires ophthalmic product portfolio from Fera for $93M theflyonthewall.com |
| 08:33AM | Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million PR Newswire |
| 13-Jun-13 04:02PM | Cartoons and Contraceptives? Questions Over Pitching Plan B Drug to Teens at Fox Business |
| 11-Jun-13 09:42PM | Lifting Restrictions of Morning After Pill Has Little Impact for Drug Maker at New York Times |
| 01:04PM | PERRIGO CO Financials EDGAR Online Financials |
| 07-Jun-13 07:00AM | [video] Perrigo Loves Babies & Puppies at TheStreet |
| 06-Jun-13 04:14PM | Perrigo begins trading on NYSE AP |
| 04:13PM | Perrigo Rises On Unusually High Volume (PRGO) at TheStreet |
| 01:47PM | Sector Snap: Makers of morning-after pill rise AP |
| 11:55AM | NYSE Euronext Welcomes Leading Global Healthcare Supplier, Perrigo Company, to the New York Stock Exchange Business Wire |
| 08:30AM | Federal appeals court orders access to contraceptive, WSJ reports theflyonthewall.com |
| 05-Jun-13 06:52PM | [$$] Court Orders Access to Contraceptive at The Wall Street Journal |
| 06:12PM | [$$] Court Orders Access to Contraceptive at The Wall Street Journal |
| 04:38PM | PRGO Makes Notable Cross Below Critical Moving Average at Forbes |
| 31-May-13 05:40PM | Patent Challenge from Perrigo Zacks |
| 12:57PM | Netflix bulls, bears argue about firm rejoining Nasdaq 100 at Investor's Business Daily |
| 11:50AM | Apple, Netflix among advancers as techs rise at MarketWatch |
| 10:29AM | Stocks headed for May gains at CNNMoney.com |
| 09:51AM | Stocks headed for May gains at CNNMoney.com |
| 09:15AM | Premarkets: Stocks headed for May gains at CNNMoney.com |
| 07:30AM | Premarkets: Stocks headed for May gains at CNNMoney.com |
| 07:23AM | Premarkets: Stocks headed for May gains at CNNMoney.com |
| 07:06AM | Sell in May, What the Hay; U.S. Wheat Ban; Dell and Sony Developments Hot Stock Minute |
| 07:02AM | Netflix to join the Nasdaq-100 index next week AP |
| 30-May-13 08:05PM | Netflix, Inc. to Join the NASDAQ-100 Index Beginning June 6, 2013 GlobeNewswire |
| 29-May-13 12:32PM | Three Unique Medical Niche Companies at Motley Fool |
| 10:53AM | Perrigo seeks approval of generic Axiron AP |
| 08:09AM | InPlay: Perrigo confirms patent challenge for generic version of Axiron Topical Solution Briefing.com |
| 08:01AM | Perrigo Confirms Patent Challenge For Generic Version Of Axiron® Topical Solution PR Newswire |
| 07:54AM | InPlay: Perrigo announces FDA final approval for generic equivalent to Sanctura XR Briefing.com |
| 07:54AM | Perrigo Announces FDA Final Approval For Generic Equivalent To Sanctura XR® PR Newswire |
| 28-May-13 03:07PM | PRGO Ex-Dividend Reminder - 5/29/13 at Forbes |
| 09:55AM | Perrigo Stock To Go Ex-dividend Tomorrow (PRGO) at TheStreet |
| 25-May-13 05:00PM | Perrigo Discount Widens After U.S. Stock Jumps: Israel Overnight at Bloomberg |
| 23-May-13 11:01AM | Perrigo to transfer stock to NYSE AP |
| 08:15AM | Perrigo to transfer common listing to NYSE from Nasdaq theflyonthewall.com |
| 08:15AM | InPlay: Perrigo to transfter common stock listing to NYSE from the NASDAQ Global Select Market Briefing.com |
| 08:14AM | Perrigo To Transfer Common Stock Listing To NYSE PR Newswire |
| 01:27AM | PERRIGO CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf EDGAR Online |
| 20-May-13 09:51AM | 2 Healthcare Companies And 1 Consumer Goods Company With Recent Intensive Insider Selling at Seeking Alpha |
| 18-May-13 08:00AM | The New Generic-Drug Battle Front at Motley Fool |
| 17-May-13 11:50AM | Good News For Health Care Stocks Part 2 at Motley Fool |
| 16-May-13 09:38AM | PERRIGO CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 15-May-13 03:50PM | Perrigo Stock Hits New 52-Week High (PRGO) at TheStreet |
| 14-May-13 01:28PM | InPlay: Perrigo notches new session high of 120.15 between its multi-year close high and last week's intraday high at 120.08/120.30 Briefing.com |
| 13-May-13 10:54AM | Perrigo Launches First-Ever Industry Marketing Campaign For Store Brand OTC Medications PR Newswire |
| 11-May-13 06:43PM | These 4 Stocks Saw Trading Price Swings This Past Week Post Earnings at Wall St. Cheat Sheet |
| 01:04PM | PERRIGO CO Financials EDGAR Online Financials |
| 10-May-13 03:28PM | Perrigo Becomes #16 Most Shorted Nasdaq 100 Component, Replacing Intuit at TheStreet |
| 10:22AM | Cramer Says Sell Teva Pharmaceutical, But Buy SunTrust Banks and These 2 Stocks at Wall St. Cheat Sheet |
| 06:00AM | Cramer's Top Stock Picks: PRGO OPEN YELP GRPN at TheStreet |
| 01:31AM | PERRIGO CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 09-May-13 08:17PM | Cramer's 'Mad Money' Recap: Looking for Real Leaders at TheStreet |
| 06:15PM | [video] Perrigo CEO: Mucinex Product Will Be a Big Winner at CNBC |
| 06:14PM | Cramer's Trend Watch: Store Brand Drugs at CNBC |
| 09:07AM | Perrigo Company Earnings Call Nuggets: Consumer Business and Cash Priorities at Wall St. Cheat Sheet |
| 07-May-13 05:01PM | Perrigo Company (PRGO): Today's Featured Health Care Laggard at TheStreet |
| 03:01PM | Perrigo Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 01:03PM | 4 Stocks Pushing The Drugs Industry Downward at TheStreet |
| 12:10PM | Earnings Miss at Perrigo Zacks |
| 11:43AM | [video] Tuesday's Earnings Scorecard at CNBC |
| 09:46AM | Perrigo Co. Earnings: Heres Why Shares are Down Now at Wall St. Cheat Sheet |
| 07:53AM | BRIEF-Perrigo shares down following results at Reuters |
| 07:48AM | InPlay: Perrigo misses by $0.02, misses on revs; reaffirms FY13 EPS guidance Briefing.com |
| 07:43AM | Perrigo Reports Record Revenue and Adjusted Earnings PR Newswire |
| 07:23AM | Perrigo - A Healthy Bet For Your Portfolio at Seeking Alpha |
| 07:07AM | Q3 2013 Perrigo Company Earnings Release - 08:00 am ET CCBN |
| 01:38AM | PERRIGO CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 06-May-13 03:00PM | Perrigo Likely to Report In Line Earnings Zacks |
| 10:10AM | Forbes Earnings Preview: Perrigo Company at Forbes |
| 03-May-13 05:43PM | Perrigo Goes With $0.09 Quarterly Dividend at Motley Fool |
| 02-May-13 12:47PM | Daily Dividend Report: HAR, STX, STJ, PRGO, RDS at Forbes |
| 11:31AM | Key for Big Generic Players is Focusing on Higher Value Opportunities that Provide Sustainable Cash Flows: Expert Analyst David Amsellem Discusses the Pharmaceutical Sector with The Wall Street Transcript Wall Street Transcript |
| 08:40AM | Perrigo Company Announces Quarterly Dividend PR Newswire |
| 01-May-13 09:55AM | 3 Healthcare Picks From Janus Fund at Motley Fool |
| 30-Apr-13 04:49PM | Scared of a Market Fall? Watch These Defensive Growth Stocks at Motley Fool |
| 27-Apr-13 03:06PM | AbbVie Q1: Story of Humira and the 7 Dwarfs at Motley Fool |
| 26-Apr-13 02:10PM | Covidien's 2Q Earnings Beat Zacks |
| 25-Apr-13 02:00PM | Stryker's 1Q Earnings Beat Est.; Sales Lag Zacks |
| 24-Apr-13 06:20PM | How Will AbbVie's Earnings Fare? at Motley Fool |
| 23-Apr-13 02:19PM | Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013 PR Newswire |
| 22-Apr-13 09:37AM | Is Perrigo a Stealth Superstar? at Wall St. Cheat Sheet |
| 17-Apr-13 01:45PM | Covidien Collaborates with VIDA Zacks |
| 14-Apr-13 12:45AM | My Thoughts On Taro at Seeking Alpha |
| 12-Apr-13 02:14PM | Landmark Judgment Could Give These Stocks a Boost at Motley Fool |
| 04-Apr-13 10:28AM | Valeant EPS Outlook Hit By Surprise Generic Approval at Investor's Business Daily |
| 03-Apr-13 07:58AM | Perrigo Touches 52-Week High Zacks |
| 02-Apr-13 04:13PM | Perrigo Buys Velcera Zacks |
| 01:20PM | Perrigo Achieves #179 Analyst Rank, Surpassing Microchip Technology at Forbes |
| 12:29PM | Perrigo Stock Hits New 52-Week High (PRGO) at TheStreet |
| 01-Apr-13 05:54PM | Perrigo Closes Acquisition of Pet Health Products Company at Motley Fool |
| 10:49AM | Perrigo Acquisition Of Velcera, Inc. -- Known For Its PetArmor® Franchise Of Flea And Tick Treatments -- Closes Today PR Newswire |
| 09:17AM | Perrigo Company Closes Acquisition Of Companion Animal Health Company, Velcera, Inc. PR Newswire |
| 22-Mar-13 09:00AM | The Pomerantz Firm, Glancy Binkow & Goldberg LLP, and Robbins Geller Rudman & Dowd LLP announce the Notice of Proposed Settlement of the In re: Perrigo Company Securities Litigation PR Newswire |
| 21-Mar-13 02:08PM | Perrigo Ships Mucinex Generic Zacks |
| 18-Mar-13 09:00AM | Perrigo to Begin Shipments of Guaifenesin Extended-Release 600mg Tablets, the First Store Brand Equivalents to Mucinex® 600mg Extended Release Tablets PR Newswire |
| 13-Mar-13 06:34PM | Will Testosterone Fuel Biotech's Next Great Race? at Motley Fool |
|
 |
| Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. The company operates in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, and API. The Consumer Healthcare segment offers a line of OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, and smoking cessation, as well as in the areas of feminine hygiene, diabetes care, and dermatological care. The Nutritionals segment develops, manufactures, markets, and distributes infant and toddler formula products, infant and toddler foods, and oral electrolyte solution products, as well as vitamin, mineral, and dietary supplement products. The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription drug products in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, and oral liquids and oral solid dosage forms. The API segment develops, manufactures, and markets API used by the generic drug industry and branded pharmaceutical companies. Perrigo Company also manufactures and markets branded prescription drugs; and imports pharmaceutical, diagnostics, and other medical products. The company sells its products through chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations, as well as retail drug, supermarket, and mass merchandise chains. It has joint development agreements with Medicis Pharmaceutical Corporation, and M. Arkin, Ltd. Perrigo Company was founded in 1887 and is headquartered in Allegan, Michigan. |
 |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| KINGMA TODD W | Executive VP, General Counsel | Jun 14 | Option Exercise | 35.85 | 1,250 | 44,813 | 18,315 | Jun 18 10:47 AM | | PAPA JOSEPH C | President and CEO | Jun 14 | Option Exercise | 35.85 | 10,000 | 358,500 | 110,000 | Jun 18 10:49 AM | | PAPA JOSEPH C | President and CEO | Jun 14 | Sale | 118.39 | 10,000 | 1,183,910 | 100,000 | Jun 18 10:49 AM | | KINGMA TODD W | Executive VP, General Counsel | Jun 14 | Sale | 118.00 | 1,250 | 147,500 | 17,065 | Jun 18 10:47 AM | | Brown Judy L | Executive VP & CFO | Jun 04 | Option Exercise | 30.06 | 2,500 | 75,150 | 19,933 | Jun 06 02:31 PM | | Brown Judy L | Executive VP & CFO | Jun 04 | Sale | 116.38 | 2,500 | 290,950 | 17,433 | Jun 06 02:31 PM | | Shah Jatin | Sr VP & Chief Scientific Offic | May 17 | Option Exercise | 15.47 | 3,120 | 48,266 | 3,520 | May 21 03:19 PM | | Shah Jatin | Sr VP & Chief Scientific Offic | May 17 | Sale | 119.60 | 2,268 | 271,260 | 1,900 | May 21 03:19 PM | | KINGMA TODD W | Executive VP, General Counsel | May 16 | Sale | 120.21 | 1,400 | 168,298 | 17,065 | May 20 08:40 AM | | PAPA JOSEPH C | President and CEO | May 15 | Option Exercise | 35.85 | 5,000 | 179,250 | 105,000 | May 17 12:12 PM | | PAPA JOSEPH C | President and CEO | May 15 | Sale | 120.51 | 5,000 | 602,567 | 100,000 | May 17 12:12 PM | | Kochan Sharon | Executive VP U.S. Generics | May 14 | Option Exercise | 58.82 | 2,647 | 155,697 | 8,139 | May 16 03:02 PM | | Shah Jatin | Sr VP & Chief Scientific Offic | May 14 | Sale | 119.77 | 3,672 | 439,785 | 1,490 | May 16 03:06 PM | | Kochan Sharon | Executive VP U.S. Generics | May 14 | Sale | 119.64 | 2,647 | 316,687 | 5,492 | May 16 03:02 PM | | Gottfried Ran | Director | May 13 | Option Exercise | 59.74 | 2,224 | 132,862 | 13,833 | May 15 10:16 AM | | Stewart Michael Robert | Sr. VP Global Human Resources | May 13 | Option Exercise | 20.50 | 1,560 | 31,980 | 1,560 | May 15 10:17 AM | | Gottfried Ran | Director | May 13 | Sale | 119.53 | 2,224 | 265,843 | 11,609 | May 15 10:16 AM | | Stewart Michael Robert | Sr. VP Global Human Resources | May 13 | Sale | 119.68 | 4,092 | 489,721 | 0 | May 15 10:17 AM | | Brown Judy L | Executive VP & CFO | May 07 | Option Exercise | 30.06 | 2,500 | 75,150 | 19,933 | May 09 10:23 AM | | Brown Judy L | Executive VP & CFO | May 07 | Sale | 116.86 | 2,500 | 292,150 | 17,433 | May 09 10:23 AM | | KINGMA TODD W | Executive VP, General Counsel | May 03 | Option Exercise | 35.85 | 1,250 | 44,813 | 19,715 | May 07 12:29 PM | | KINGMA TODD W | Executive VP, General Counsel | May 03 | Sale | 119.69 | 1,250 | 149,613 | 18,465 | May 07 12:29 PM | | PAPA JOSEPH C | President and CEO | Apr 09 | Option Exercise | 30.06 | 5,000 | 150,300 | 110,645 | Apr 11 02:49 PM | | PAPA JOSEPH C | President and CEO | Apr 09 | Sale | 118.46 | 10,645 | 1,261,046 | 100,000 | Apr 11 02:49 PM | | Brown Judy L | Executive VP & CFO | Apr 02 | Option Exercise | 30.06 | 2,500 | 75,150 | 19,933 | Apr 04 05:43 PM | | Farrington Thomas | Senior VP and CIO | Apr 02 | Option Exercise | 58.82 | 927 | 54,526 | 1,967 | Apr 04 05:48 PM | | Brown Judy L | Executive VP & CFO | Apr 02 | Sale | 119.07 | 2,500 | 297,675 | 17,433 | Apr 04 05:43 PM | | Farrington Thomas | Senior VP and CIO | Apr 02 | Sale | 120.00 | 927 | 111,240 | 1,040 | Apr 04 05:48 PM | | PAPA JOSEPH C | President and CEO | Mar 12 | Option Exercise | 30.06 | 5,000 | 150,300 | 110,645 | Mar 14 04:15 PM | | PAPA JOSEPH C | President and CEO | Mar 12 | Sale | 116.33 | 15,000 | 1,744,942 | 105,645 | Mar 14 04:15 PM | | Yu Louis | Senior VP Global Quality | Mar 06 | Option Exercise | 30.06 | 1,795 | 53,958 | 10,966 | Mar 08 01:57 PM | | Yu Louis | Senior VP Global Quality | Mar 06 | Sale | 116.07 | 1,795 | 208,348 | 9,171 | Mar 08 01:57 PM | | Brown Judy L | Executive VP & CFO | Mar 05 | Option Exercise | 30.06 | 2,500 | 75,150 | 19,933 | Mar 07 02:28 PM | | Zilberfarb Ben-Zion | Director | Mar 05 | Sale | 115.09 | 2,790 | 321,110 | 2,553 | Mar 07 02:32 PM | | Brown Judy L | Executive VP & CFO | Mar 05 | Sale | 115.42 | 2,500 | 288,547 | 17,433 | Mar 07 02:28 PM | | MORRIS HERMAN JR | Director | Mar 05 | Sale | 114.75 | 200 | 22,950 | 2,400 | Mar 07 04:13 PM | | PAPA JOSEPH C | President and CEO | Feb 14 | Option Exercise | 30.06 | 5,000 | 150,300 | 120,645 | Feb 19 12:36 PM | | PAPA JOSEPH C | President and CEO | Feb 14 | Sale | 112.07 | 5,000 | 560,369 | 115,645 | Feb 19 12:36 PM | | Yu Louis | Senior VP Global Quality | Feb 12 | Option Exercise | 20.50 | 3,328 | 68,224 | 12,499 | Feb 14 11:56 AM | | Yu Louis | Senior VP Global Quality | Feb 12 | Sale | 111.57 | 3,328 | 371,315 | 9,171 | Feb 14 11:56 AM | | PAPA JOSEPH C | President and CEO | Jan 17 | Option Exercise | 30.06 | 5,000 | 150,300 | 120,645 | Jan 22 02:37 PM | | PAPA JOSEPH C | President and CEO | Jan 17 | Sale | 104.50 | 5,000 | 522,493 | 115,645 | Jan 22 02:37 PM | | Jamison Scott F | Executive Vice President PBM | Jan 03 | Option Exercise | 108.02 | 1,000 | 108,020 | 3,361 | Jan 04 12:41 PM | | PAPA JOSEPH C | President and CEO | Dec 14 | Option Exercise | 23.17 | 15,000 | 347,595 | 130,645 | Dec 18 04:58 PM | | PAPA JOSEPH C | President and CEO | Dec 14 | Sale | 103.94 | 15,000 | 1,559,118 | 115,645 | Dec 18 04:58 PM | | JANDERNOA MICHAEL J | Director | Dec 07 | Sale | 102.49 | 105,500 | 10,812,590 | 495,230 | Dec 11 01:15 PM | | JANDERNOA MICHAEL J | Director | Dec 06 | Sale | 103.50 | 67,500 | 6,986,000 | 609,645 | Dec 07 03:42 PM | | JANDERNOA MICHAEL J | Director | Dec 05 | Sale | 105.00 | 72,000 | 7,559,705 | 973,145 | Dec 07 03:42 PM | | Gottfried Ran | Director | Dec 04 | Option Exercise | 39.62 | 3,053 | 120,960 | 14,662 | Dec 06 10:13 AM | | Gottfried Ran | Director | Dec 04 | Sale | 104.47 | 3,053 | 318,947 | 11,609 | Dec 06 10:13 AM | | BRLAS LAURIE | Director | Dec 03 | Sale | 102.77 | 10,757 | 1,105,465 | 7,424 | Dec 05 01:36 PM | | Farrington Thomas | Senior VP and CIO | Nov 29 | Option Exercise | 20.50 | 978 | 20,049 | 1,653 | Dec 03 01:15 PM | | Farrington Thomas | Senior VP and CIO | Nov 29 | Sale | 103.16 | 613 | 63,238 | 1,040 | Dec 03 01:15 PM | | GIBBONS DAVID T | Director | Nov 26 | Option Exercise | 25.88 | 30,778 | 796,410 | 29,125 | Nov 28 03:33 PM | | KINGMA TODD W | Executive VP, General Counsel | Nov 26 | Option Exercise | 30.06 | 2,740 | 82,364 | 21,205 | Nov 28 03:33 PM | | GIBBONS DAVID T | Director | Nov 26 | Sale | 102.29 | 50,778 | 5,194,204 | 11,625 | Nov 28 03:33 PM | | KINGMA TODD W | Executive VP, General Counsel | Nov 26 | Sale | 103.28 | 2,740 | 282,994 | 18,465 | Nov 28 03:33 PM | | PAPA JOSEPH C | President and CEO | Nov 15 | Option Exercise | 30.06 | 15,000 | 450,900 | 130,645 | Nov 19 02:04 PM | | PAPA JOSEPH C | President and CEO | Nov 15 | Sale | 100.78 | 15,000 | 1,511,747 | 115,645 | Nov 19 02:04 PM | | Kochan Sharon | Executive VP U.S. Generics | Nov 14 | Option Exercise | 20.50 | 2,912 | 59,696 | 7,772 | Nov 16 03:08 PM | | MORRIS HERMAN JR | Director | Nov 09 | Sale | 103.90 | 2,000 | 207,804 | 17,980 | Nov 13 09:23 AM | | KINGMA TODD W | Executive VP, General Counsel | Oct 25 | Option Exercise | 30.06 | 3,500 | 105,210 | 21,965 | Oct 29 05:17 PM | | KINGMA TODD W | Executive VP, General Counsel | Oct 25 | Sale | 117.87 | 4,500 | 530,434 | 18,465 | Oct 29 05:17 PM | | PAPA JOSEPH C | President and CEO | Oct 10 | Option Exercise | 30.06 | 15,000 | 450,900 | 130,645 | Oct 12 11:58 AM | | PAPA JOSEPH C | President and CEO | Oct 10 | Sale | 117.37 | 15,000 | 1,760,554 | 115,645 | Oct 12 11:58 AM | | Brown Judy L | Executive VP & CFO | Oct 08 | Option Exercise | 20.50 | 2,679 | 54,920 | 20,812 | Oct 10 03:30 PM | | Brown Judy L | Executive VP & CFO | Oct 08 | Sale | 119.24 | 2,679 | 319,447 | 18,133 | Oct 10 03:30 PM | | Farrington Thomas | Senior VP and CIO | Oct 04 | Option Exercise | 58.82 | 926 | 54,467 | 1,601 | Oct 09 08:21 AM | | Farrington Thomas | Senior VP and CIO | Oct 04 | Sale | 120.00 | 926 | 111,120 | 675 | Oct 09 08:21 AM | | KINGMA TODD W | Executive VP, General Counsel | Sep 25 | Option Exercise | 20.50 | 3,565 | 73,083 | 23,030 | Sep 27 08:33 AM | | KINGMA TODD W | Executive VP, General Counsel | Sep 25 | Sale | 117.28 | 3,565 | 418,103 | 19,465 | Sep 27 08:33 AM | | PAPA JOSEPH C | President and CEO | Sep 21 | Option Exercise | 30.06 | 15,000 | 450,900 | 130,645 | Sep 25 04:45 PM | | PAPA JOSEPH C | President and CEO | Sep 21 | Sale | 116.59 | 15,000 | 1,748,831 | 115,645 | Sep 25 04:45 PM | | Jamison Scott F | Executive Vice President PBM | Sep 14 | Option Exercise | 112.45 | 1,000 | 112,450 | 2,684 | Sep 18 02:43 PM | | Brown Judy L | Executive VP & CFO | Sep 06 | Option Exercise | 20.50 | 2,678 | 54,899 | 20,811 | Sep 07 03:10 PM | | Brown Judy L | Executive VP & CFO | Sep 06 | Sale | 110.81 | 2,678 | 296,749 | 18,133 | Sep 07 03:10 PM | | KINGMA TODD W | Executive VP, General Counsel | Aug 30 | Option Exercise | 20.50 | 2,000 | 41,000 | 21,465 | Sep 04 03:51 PM | | Needham Jeffrey | Sr. VP Commercial Business Dev | Aug 30 | Option Exercise | 20.50 | 2,080 | 42,640 | 7,268 | Aug 31 01:46 PM | | HENDRICKSON JOHN T | EVP Global Operations & Supply | Aug 30 | Option Exercise | 20.50 | 3,589 | 73,575 | 3,589 | Sep 04 03:52 PM | | PAPA JOSEPH C | President and CEO | Aug 30 | Option Exercise | 20.50 | 10,000 | 205,000 | 125,645 | Sep 04 03:52 PM | | HENDRICKSON JOHN T | EVP Global Operations & Supply | Aug 30 | Sale | 108.87 | 3,589 | 390,734 | 0 | Sep 04 03:52 PM | | KINGMA TODD W | Executive VP, General Counsel | Aug 30 | Sale | 108.87 | 2,000 | 217,740 | 19,465 | Sep 04 03:51 PM | | Needham Jeffrey | Sr. VP Commercial Business Dev | Aug 30 | Sale | 108.87 | 2,080 | 226,450 | 5,188 | Aug 31 01:46 PM | | PAPA JOSEPH C | President and CEO | Aug 30 | Sale | 109.17 | 10,000 | 1,091,741 | 115,645 | Sep 04 03:52 PM | | Needham Jeffrey | Sr. VP Commercial Business Dev | Aug 29 | Option Exercise | 55.01 | 6,665 | 366,615 | 8,240 | Aug 31 01:46 PM | | Needham Jeffrey | Sr. VP Commercial Business Dev | Aug 29 | Sale | 110.34 | 9,224 | 1,017,732 | 5,188 | Aug 31 01:46 PM | | Stewart Michael Robert | Sr. VP Global Human Resources | Aug 28 | Option Exercise | 54.33 | 3,883 | 210,959 | 4,327 | Aug 29 02:42 PM | | HENDRICKSON JOHN T | EVP Global Operations & Supply | Aug 28 | Sale | 110.66 | 6,666 | 737,633 | 0 | Aug 29 03:17 PM | | Kochan Sharon | Executive VP U.S. Generics | Aug 28 | Sale | 110.80 | 3,352 | 371,402 | 4,860 | Aug 29 03:14 PM | | Stewart Michael Robert | Sr. VP Global Human Resources | Aug 28 | Sale | 110.90 | 7,633 | 846,533 | 2,532 | Aug 29 02:42 PM | | KINGMA TODD W | Executive VP, General Counsel | Aug 28 | Sale | 110.66 | 5,000 | 553,279 | 19,465 | Aug 29 03:12 PM | | Brown Judy L | Executive VP & CFO | Aug 28 | Sale | 110.65 | 12,180 | 1,347,741 | 18,133 | Aug 29 03:12 PM | | Brown Judy L | Executive VP & CFO | Aug 27 | Option Exercise | 110.66 | 20,575 | 2,276,830 | 33,469 | Aug 29 03:12 PM | | Stewart Michael Robert | Sr. VP Global Human Resources | Aug 27 | Option Exercise | 110.66 | 5,309 | 587,494 | 6,868 | Aug 29 02:42 PM | | KINGMA TODD W | Executive VP, General Counsel | Aug 27 | Option Exercise | 110.66 | 11,514 | 1,274,139 | 25,057 | Aug 29 03:12 PM | | Needham Jeffrey | Sr. VP Commercial Business Dev | Aug 27 | Option Exercise | 110.66 | 9,025 | 998,707 | 9,083 | Aug 29 03:13 PM | | Yu Louis | Senior VP Global Quality | Aug 27 | Option Exercise | 110.66 | 3,313 | 366,617 | 8,803 | Aug 29 03:13 PM | | Kochan Sharon | Executive VP U.S. Generics | Aug 27 | Option Exercise | 90.29 | 10,657 | 962,248 | 11,593 | Aug 29 03:14 PM | | Shah Jatin | Sr VP & Chief Scientific Offic | Aug 27 | Option Exercise | 110.66 | 6,191 | 685,096 | 8,273 | Aug 29 03:16 PM | | HENDRICKSON JOHN T | EVP Global Operations & Supply | Aug 27 | Option Exercise | 90.29 | 14,210 | 1,283,044 | 10,257 | Aug 29 03:17 PM |
|
 |
|
|
 |
|